All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Lisaftoclax approved by China’s NMPA for adult patients with CLL/SLL
On July 10, 2025, China’s National Medical Products Administration (NMPA) granted approval for lisaftoclax (APG-2575), a novel, oral, B-cell lymphoma 2 (BCL-2) inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received ≥1 systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.1
This approval is based on results from the registrational phase II APG2575CC201 trial (NCT05147467), which assessed the efficacy and safety of lisaftoclax monotherapy in patients with relapsed/refractory (R/R) CLL/SLL.1 The primary endpoint of overall response rate (ORR) was met in patients who were previously treated with a BTK inhibitor and/or immunochemotherapy.1 The safety profile was manageable, with no tumor lysis syndrome reported and low incidences of hematologic and non-hematologic toxicities.1
Lisaftoclax is currently under evaluation in four global phase III trials:
GLORA (NCT06104566): lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with a BTK inhibitor for >12 months with suboptimal response.
GLORA-2 (NCT06319456): lisaftoclax in combination with acalabrutinib vs immunochemotherapy in newly diagnosed patients with CLL/SLL.
GLORA-3 (NCT06389292): lisaftoclax in combination with azacitidine in newly diagnosed, elderly, and unfit patients with acute myeloid leukemia (AML).
GLORA-4 (NCT06641414): lisaftoclax in combination with azacitidine in newly diagnosed patients with higher-risk myelodysplastic syndromes (MDS).
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?
